Search

Your search keyword '"O'Hehir R"' showing total 526 results

Search Constraints

Start Over You searched for: Author "O'Hehir R" Remove constraint Author: "O'Hehir R"
526 results on '"O'Hehir R"'

Search Results

1. Evaluation of Diagnosis and Management of Omega-5-Gliadin Allergy: A Retrospective Survey

2. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis

3. Rhinitis associated with asthma is distinct from rhinitis alone:The ARIA-MeDALL hypothesis

4. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

5. The ARIA-MeDALL hypothesis

6. Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study

8. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

9. Update about Oralair (R) as a treatment for grass pollen allergic rhinitis

10. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

11. Development and validation of combined symptom-medication scores for allergic rhinitis*

12. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

13. Evaluation of Diagnosis and Management of Omega-5-Gliadin Allergy: A Retrospective Survey.

14. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic - an EAACI/ARIA Position Paper

15. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

16. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

17. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

18. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

19. Effect of structural stability on endolysosomal degradation and T‐cell reactivity of major shrimp allergen tropomyosin

20. Aligning the Good Practice MASK With the Objectives of the European Innovation Partnership on Active and Healthy Ageing

21. Rapid and lasting generation of B-cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 disease and convalescence

22. Effect of structural stability on endolysosomal degradation and T-cell reactivity of major shrimp allergen tropomyosin

23. Introduction to Mechanisms of Allergic Diseases

24. Adherence to treatment in allergic rhinitis using mobile technology. the mask study

25. ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

26. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

27. 2019 ARIA Care pathways for allergen immunotherapy

28. 2019 ARIA Care pathways for allergen immunotherapy [ARIA-Versorgungspfade für die Allergenimmuntherapie 2019]

29. Next-generation ARIA care pathways for rhinitis and asthma: A model for multimorbid chronic diseases

30. 2019 ARIA Care pathways for allergen immunotherapy

32. ARIA pharmacy 2018 'Allergic rhinitis care pathways for community pharmacy'

33. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018) : Change management in allergic rhinitis and asthma multimorbidity using mobile technology

34. Next-generation ARIA care pathways for rhinitis and asthma: A model for multimorbid chronic diseases

35. Hypotensive episodes associated with azithromycin infusion: a potentially fatal adverse drug reaction

36. Continued loss of asthma control following epidemic thunderstorm asthma

37. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma.

38. State‐of‐the‐art in marketed adjuvants and formulations in Allergen Immunotherapy: a position paper of the European Academy of Allergy and Clinical Immunology (EAACI)

41. Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)(Clin Transl Allergy (2016) 6 (29) DOI: 10.1186/s13601-016-0116-9)

42. Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control

43. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement

44. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

45. Mask 2017: Aria Digitally-Enabled, Integrated, Person-Centred Care For Rhinitis And Asthma Multimorbidity Using Real-World-Evidence

46. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

47. Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study

50. Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)

Catalog

Books, media, physical & digital resources